Phosphorylation of cMyBP-C Modulates Cardiac Arrhythmias

cMyBP-C 磷酸化调节心律失常

• 批准号: 8763886
• 负责人: Ramzi J Khairallah
• 金额: $ 5.31万
• 依托单位: LOYOLA UNIVERSITY CHICAGO
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-30 至 2015-09-01
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8763886
• 关键词: Actins; Action Potentials; Actomyosin Adenosinetriphosphatase; Adrenergic Agents; Animal Model; Animals; Arrhythmia; Atrial Fibrillation; Binding; Binding Proteins; Caffeine; Calcium; Cardiac; Cardiac Death; Cardiac Myocytes; Cardiac Myosins; Cell physiology; Cells; Cessation of life; Clinical; Conscious; Depressed mood; Development; Diagnosis; Dose; Electrocardiogram; Environment; Event; Frequencies; Genes; Goals; Heart; Heart Atrium; Heart failure; Hypertrophic Cardiomyopathy; Hypertrophy; Implant; Incidence; Injury; Interdisciplinary Study; Investigation; Ischemia; Isometric Exercise; Isoproterenol; Kinetics; Lead; Length; Link; Measures; Mentors; Methods; Microfilaments; Molecular; Monitor; Movement; Mus; Muscle Cells; Mutant Strains Mice; Mutation; Myocardial; Myocardium; Myosin ATPase; Organ; Pathogenesis; Pathologic; Patients; Phenotype; Phosphorylation; Pilot Projects; Play; Prevalence; Proteins; Protocols documentation; Pump; Recurrence; Regulation; Resistance; Role; Sarcomeres; Stress; Stress Tests; Structure; Telemetry; Thick Filament; Transducers; Transgenic Animals; Transgenic Mice; Ventricular; Ventricular Dysfunction; Ventricular Premature Complexes; Ventricular Tachycardia; Vertebral column; Work; adrenergic; blebbistatin; flexibility; heart rate variability; improved functioning; in vivo; insight; myosin-binding protein C; new therapeutic target; novel; novel strategies; novel therapeutics; pressure; prevent; public health relevance; research study; response; skeletal; subcutaneous; success; sudden cardiac death; tool

DESCRIPTION (provided by applicant): A recurrent clinical hallmark of heart failure (HF) is the occurrence of arrhythmias, which contribute to the increased incidence of sudden cardiac death in HF patients and can in turn also lead to worsening HF. Despite the clear link between HF and arrhythmia, no applicable treatment has been identified specifically targeting these electrical abnormalities. The PI and his mentors have recently discovered that cardiac myosin binding protein c (cMyBP-C) phosphorylation might play a role in modulating calcium (Ca2+) handling in the heart. This can have profound implications in understanding the mechanism leading to arrhythmia during HF and might identify novel therapeutic strategies. Indeed, cMyBP-C phosphorylation is extensively phosphorylated in the healthy heart and severely depleted in HF, pathological hypertrophy, ischemic injury and atrial fibrillation. The planned investigation will exploit well established methods of assessing cardiac function in vivo, as well as develop and refine novel tools to further extend the in vivo findings into single isolated cardiac ventricuar myocytes. Work by the PI and his mentors has established several transgenic animal models that will be critical to study how cMyBP-C can lead to arrhythmogenesis, and show that mice harboring mutations preventing phosphorylation of cMyBP-C display severe arrhythmia and cardiac death following adrenergic stress. We hypothesize that cMyBP-C phosphorylation is necessary for proper Ca2+ handling in the myocardium. Therefore, the overall objectives of this proposal are to: 1) determine the propensity for arrhythmias in mice harboring mutations ablating (AllP-) or mimicking (AllP+) phosphorylation of cMyBP-C, 2) investigate the molecular causes of altered Ca2+ in isolated cardiomyocytes. The unique feature of the proposed work is the combination of in depth in vivo study and single cell experiments in a richly interactive environment with a strong record of success in such work. For the PI, the investigation nicely supports his long-term plan of conducting interdisciplinary research related to cardiac function, with the prospect of broadening our understanding of the pathogenesis of heart failure.

描述（由申请人提供）：心衰（HF）的一个复发性临床标志是心律失常的发生，心律失常会增加心衰患者心源性猝死的发生率，进而导致心衰恶化。尽管心衰和心律失常之间有明确的联系，但目前还没有确定专门针对这些电异常的适用治疗方法。PI和他的导师最近发现心肌肌球蛋白结合蛋白c （cMyBP-C）磷酸化可能在调节心脏中的钙（Ca2+）处理中起作用。这对理解心衰期间心律失常的机制具有深远的意义，并可能确定新的治疗策略。事实上，cMyBP-C磷酸化在健康心脏中被广泛磷酸化，而在HF、病理性肥厚、缺血性损伤和房颤中被严重磷酸化。计划中的研究将利用已建立的评估体内心脏功能的方法，以及开发和完善新的工具，以进一步将体内研究结果扩展到单个分离的心室肌细胞。PI和他的导师的工作已经建立了几个转基因动物模型，这对于研究cMyBP-C如何导致心律失常至关重要，并表明携带阻止cMyBP-C磷酸化的突变的小鼠在肾上腺素能应激后表现出严重的心律失常和心脏死亡。我们假设cMyBP-C磷酸化对于心肌中适当的Ca2+处理是必要的。因此，本提案的总体目标是：1)确定携带突变消融（AllP-）或模仿（AllP+） cMyBP-C磷酸化的小鼠的心律失常倾向，2)研究分离心肌细胞中Ca2+改变的分子原因。所提出的工作的独特之处在于将深入的体内研究和单细胞实验结合在一个丰富的互动环境中，并在此类工作中取得了成功。对于PI来说，这项研究很好地支持了他进行与心功能相关的跨学科研究的长期计划，并有望拓宽我们对心力衰竭发病机制的理解。